|51.00||-1.90||-3.59%||Vol 568.85K||1Y Perf 46.57%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||84.40||Analyst Rating||Strong Buy 1.54|
|Potential %||65.49||Finscreener Ranking||★★★★ 53.71|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 53.70|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 78.04|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||27.95||Earnings Rating||Sell|
|Market Cap||6.20B||Earnings Date||4th Nov 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||-0.51|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||656.91K|
|Avg. Monthly Volume||576.06K|
|Avg. Quarterly Volume||589.45K|
Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 51 per share at the end of the most recent trading day (a -3.59% change compared to the prior day closing price) with a volume of 569.56K shares and market capitalization of 6.20B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.
The one-year performance of Denali Therapeutics Inc. stock is 46.57%, while year-to-date (YTD) performance is -39.11%. DNLI stock has a five-year performance of %. Its 52-week range is between 34.34 and 93.94, which gives DNLI stock a 52-week price range ratio of 27.95%
Denali Therapeutics Inc. currently has a PE ratio of 80.00, a price-to-book (PB) ratio of 5.99, a price-to-sale (PS) ratio of 16.99, a price to cashflow ratio of 15.60, a PEG ratio of 2.32, a ROA of 5.19%, a ROC of 6.53% and a ROE of 7.10%. The company’s profit margin is 15.66%, its EBITDA margin is 16.70%, and its revenue ttm is $357.07 Million , which makes it $2.94 revenue per share.
Of the last four earnings reports from Denali Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.54), with a target price of $84.4, which is +65.49% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.64, ATR14 : 2.55, CCI20 : -110.26, Chaikin Money Flow : -0.01, MACD : -0.66, Money Flow Index : 31.10, ROC : -4.15, RSI : 43.94, STOCH (14,3) : 27.42, STOCH RSI : 0.51, UO : 48.45, Williams %R : -72.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $6 151), Alexander O. Schuth (Sold 157 059 shares of value $10 586 301 ), Carole Ho (Option Excercise at a value of $279 344), Carole Ho (Sold 76 135 shares of value $3 538 910 ), David P. Schenkein (Option Excercise at a value of $0), David P. Schenkein (Sold 80 000 shares of value $5 905 312 ), Douglas Bratton (Sold 64 624 shares of value $5 179 284 ), Douglas G. Cole (Option Excercise at a value of $0), Douglas K. Bratton (Sold 2 281 422 shares of value $149 271 156 ), Jay T. Flatley (Option Excercise at a value of $0), Jennifer Cook (Option Excercise at a value of $0), Marc Tessier-Lavigne (Option Excercise at a value of $1 765 275), Marc Tessier-Lavigne (Sold 294 378 shares of value $19 098 437 ), Peter S. Klein (Option Excercise at a value of $0), Robert T. Nelsen (Option Excercise at a value of $0), Ryan J. Watts (Option Excercise at a value of $0), Ryan J. Watts (Sold 233 629 shares of value $15 851 327 ), Steve E. Krognes (Option Excercise at a value of $0), Steve E. Krognes (Sold 156 768 shares of value $10 356 705 ), Vicki L. Sato (Sold 11 262 shares of value $675 934 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.